Trial Profile
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SHR1459, in Healthy Volunteers
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 13 May 2021
Price :
$35
*
At a glance
- Drugs Edralbrutinib (Primary)
- Indications B-cell lymphoma; Chronic lymphocytic leukaemia; Mantle-cell lymphoma; Non-Hodgkin's lymphoma
- Focus Adverse reactions
- Sponsors Jiangsu Hengrui Medicine Co.
- 10 May 2021 According to a TG Therapeutics media release, updated data from this study has been accepted for presentation at the American Society of Clinical Oncology (ASCO) annual meeting 2021.
- 12 Jan 2018 New trial record